Recursion Pharmaceuticals Files 8-K

TL;DR

RXRX filed a standard 8-K, no major news yet.

AI Summary

Recursion Pharmaceuticals, Inc. filed an 8-K on August 28, 2024, to report other events and financial statements. The filing does not contain specific details about new material events or financial figures within the provided text, but indicates a standard regulatory update.

Why It Matters

This filing is a routine regulatory disclosure by Recursion Pharmaceuticals, Inc., providing updates on company events and financial statements as required by the SEC.

Risk Assessment

Risk Level: low — This is a routine SEC filing with no new material information disclosed in the provided text.

Key Players & Entities

• RECURSION PHARMACEUTICALS, INC. (company) — Registrant
• August 28, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 46-4099738 (identifier) — I.R.S. Employer Identification No.
• 41 S Rio Grande Street (address) — Principal Executive Offices
• Salt Lake City, UT 84101 (address) — Principal Executive Offices
• ( 385 ) 269 - 0203 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar

Filing Documents

• rxrx-20240828.htm (8-K) — 35KB
• exhibit101-agreement.htm (EX-10.1) — 78KB
• 0001601830-24-000140.txt ( ) — 249KB
• rxrx-20240828.xsd (EX-101.SCH) — 2KB
• rxrx-20240828_lab.xml (EX-101.LAB) — 21KB
• rxrx-20240828_pre.xml (EX-101.PRE) — 12KB
• rxrx-20240828_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. As previously disclosed in the Current Report on Form 8-K of Recursion Pharmaceuticals, Inc. (the "Company") filed on August 8, 2024 (the "Prior 8-K"), the Company entered into a transaction agreement dated August 8, 2024 (the "Transaction Agreement") with Exscientia plc ("Exscientia"). The Transaction Agreement provides that, subject to the terms and conditions set forth therein, including the requisite approval of each of the Company's stockholders and Exscientia's shareholders, the Company will acquire the entire issued and to be issued share capital of Exscientia pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme of Arrangement" and such transaction, the "Transaction"). Also as disclosed in the Prior 8-K, concurrent with the execution of the Transaction Agreement, certain shareholders of Exscientia who together hold or control, in the aggregate, approximately 42% of the total outstanding share capital of Exscientia as of the date of the Transaction Agreement have entered into irrevocable undertakings (each an "Irrevocable Undertaking") with the Company pursuant to which each such shareholder agreed to, among other things, and subject to the terms and conditions set forth in the relevant Irrevocable Undertaking, vote (or to procure to have voted on their behalf) all of their shares in Exscientia in favor of all resolutions to approve and give effect to the Scheme of Arrangement and certain related matters. On August 28, 2024, Evotec SE ("Evotec"), a shareholder of Exscientia that holds or controls approximately 11% of the total outstanding share capital of Exscientia as of the date of the Transaction Agreement, executed a deed of irrevocable undertaking (the "Evotec Irrevocable Undertaking") pursuant to which Evotec agreed to, among other things, and subject to the terms and conditions set forth in the Evotec Irrevocable Undertaking, vote (or to procure to have voted on its behalf)

Forward Looking Statements

Forward Looking Statements. respective ongoing business operations; the ability of either Recursion, Exscientia or the combined company to retain key p

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Irrevocable Undertaking of Evotec SE dated August 28, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on August 28, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Michael Secora Michael Secora Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR